Vanadate, an inhibitor of stromelysin and collagenase expression, suppresses collagen induced arthritis

Journal of Rheumatology

Volumn 34, Issue 9, 2007, Pages 1802-1809

  Oliver, Stephen J ^e   Firestein, Gary S ^b   Arsenault, Larry ^c   Cruz, Tony F ^d,g   Cheng, Tammy P ^f   Banquerigo, Mona L ^a   Boyle, David L ^b   Brahn, Ernest ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Transition Therapeutics   (Canada)

Author keywords

Animal disease models; AP 1; Collagen induced arthritis; Matrix metalloproteinases; Vanadate

Indexed keywords

ACETYLCYSTEINE; ACTIVATING PROTEIN 1; BIS(MALTOLATO)OXOVANADIUM IV; COLLAGEN; COLLAGENASE; CYTOKINE; INTERLEUKIN 1ALPHA; MATRIX METALLOPROTEINASE; MESSENGER RNA; REGULATOR PROTEIN; STROMELYSIN; UNCLASSIFIED DRUG; VANADIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; ARTICULAR CARTILAGE; COLLAGEN INDUCED ARTHRITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; JOINT INJURY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOGRAPHY; RAT; SCORING SYSTEM; SYNOVIAL FLUID; TRANSMISSION ELECTRON MICROSCOPY;

ACETYLCYSTEINE; ANIMALS; ANKLE JOINT; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGENASES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-1; MATRIX METALLOPROTEINASE 3; PYRONES; RANDOM ALLOCATION; RATS; VANADATES;

EID: 35948965934     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Emonard H, Grimaud JA. Matrix metalloproteinases. A review. Cell Mol Biol 1990;36:131-53.
2. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8:221-33.
3. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007;13:333-46.
4. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
5. Krane SM, Conca W, Stephenson ML, Amento EP, Goldring MB. Mechanisms of matrix degradation in rheumatoid arthritis. Ann NY Acad Sci 1990;580:340-54.
6. Trabandt A, Gay RE, Gay S. Oncogene activation in rheumatoid synovium. APMIS 1992;100:861-75.
7. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-43.
8. Mix KS, Sporn MB, Brinckerhoff CE, Eyre D, Schurman DJ. Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis. Clin Orthop Relat Res 2004;427 Suppl:S129-S137.
9. Clark IM, Parker AE. Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 2003;7:19-34.
10. Krejsa CM, Nadler SG, Esselstyn JM, Kavanagh TJ, Ledbetter JA, Schieven GL. Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors. Redox independent activation of NF-kappa B. J Biol Chem 1997;272:11541-9.
11. Conquer JA, Grima DT, Cruz TF. Orthovanadate inhibits interleukin-1 and phorbol ester induced collagenase production by chondrocytes. Ann NY Acad Sci 1994;732:447-9.
12. Cruz TF, Mills G, Pritzker KP, Kandel RA. Inverse correlation between tyrosine phosphorylation and collagenase production in chondrocytes. Biochem J 1990;269:717-21.
13. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977;146:857-68.
14. Brahn E. Animal models of rheumatoid arthritis: clues to etiology and treatment. In: Hahn B, editor. Clinical orthopedics and related research. Philadelphia: Lippincott; 1991:42-53.
15. Brahn E, Trentham DE. Antigen-specific suppression of collagen arthritis by adoptive transfer of spleen cells. Clin Immunol Immunopathol 1984;31:124-31.
16. Brahn E, Trentham DE. Effect of antithymocyte serum on collagen arthritis in rats: evidence that T cells are involved in its pathogenesis. Cell Immunol 1984;86:421-8.
17. Brahn E, Trentham DE. Experimental synovitis induced by collagen-specific T cell lines. Cell Immunol 1989;118:491-503.
18. Boyle DL, Sajjadi FG, Firestein GS. Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 1996;39:923-30.
19. O'Gradaigh D, Ireland D, Bord S, Compston JE. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004;63:354-9.
20. Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991;34:1094-105.
21. Hu E, Mueller E, Oliviero S, Papaioannou VE, Johnson R, Spregelman BM. Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. EMBO J 1994;13:3094-103.
22. Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
23. Lo YY, Cruz TF. Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol Chem 1995;270:11727-30.
24. Wei H. Activation of oncogenes and/or inactivation of anti-oncogenes by reactive oxygen species. Med Hypotheses 1992;39:267-70.
25. 2 and N-acetyl-L-cysteine regulate expression of c-jun and c-fos in lens systems. Exp Eye Res 1994;59:179-90.
26. 2 interaction. Biochim Biophys Acta 1994;1201:289-97.
27. Abate C, Patel L, Rauscher FJ III, Curran T. Redox regulation of fos andjun DNA-binding activity in vitro. Science 1990;249:1157-61.
28. Domingo JL, Gomez M, Llobet JM, Corbella J, Keen CL. Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology 1991;66:279-87.
29. Domingo JL, Gomez M, Llobet JM, Corbella J, Keen CL. Improvement of glucose homeostasis by oral vanadyl or vanadate treatment in diabetic rats is accompanied by negative side effects. Pharmacol Toxicol 1991;68:249-53.
30. Bishayee A, Chatterjee M. Inhibition of altered liver cell foci and persistent nodule growth by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in rats. Anticancer Res 1995;15:455-61.
31. Thompson HJ, Chasteen ND, Meeker LD. Dietary vanadyl(IV) sulfate inhibits chemically-induced mammary carcinogenesis. Carcinogenesis 1984;5:849-51.
32. Sakurai H. Vanadium distribution in rats and DNA cleavage by vanadyl complex: implication for vanadium toxicity and biological effects. Environ Health Perspect 1994;102 Suppl 3:35-6.
33. Degani H, Gochin M, Karlish SJ, Shechter Y. Electron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes. Biochemistry 1981;20:5795-9.
34. Saxena AK, Srivastava P, Kale RK, Baquer NZ. Impaired antioxidant status in diabetic rat liver. Effect of vanadate. Biochem Pharmacol 1993;45:539-42.